(Q34479570)

2 August 2017

title

Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial (English)

1 reference

2 August 2017

main subject

phase III clinical trial

0 references

0 references

1 reference

Alexey Kubanov

4

0 references

Hervé Bachelez

object named as

Hervé Bachelez

José Luis López Estebaranz

1

0 references

0 references

Robert Wołk

15

object named as

Robert Wolk

1 reference

2 August 2017

Dimitar K. Gospodinov

1 reference

ORCID Public Data File 2021

author name string

Peter C M van de Kerkhof

2

1 reference

2 August 2017

Robert Strohal

3

1 reference

2 August 2017

Fernando Valenzuela

5

1 reference

2 August 2017

Joo-Heung Lee

6

1 reference

2 August 2017

Vladimir Yakusevich

7

1 reference

2 August 2017

Sergio Chimenti

8

1 reference

2 August 2017

Jocelyne Papacharalambous

9

1 reference

2 August 2017

James Proulx

10

1 reference

2 August 2017

Pankaj Gupta

11

1 reference

2 August 2017

Huaming Tan

12

1 reference

2 August 2017

Margaret Tawadrous

13

1 reference

2 August 2017

Hernan Valdez

14

1 reference

2 August 2017

OPT Compare Investigators

16

1 reference

2 August 2017

language of work or name

English

0 references

publication date

4 June 2015

1 reference

2 August 2017

1 reference

2 August 2017

volume

386

1 reference

2 August 2017

issue

9993

1 reference

2 August 2017

page(s)

552-561

1 reference

Psoriasis causes as much disability as other major medical diseases

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962113-9

7 January 2021

New insights in the immunologic basis of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962113-9

7 January 2021

Pathogenesis and therapy of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962113-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962113-9

1 reference

7 January 2021

Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962113-9

7 January 2021

PUVA, UVB, psoriasis, and nonmelanoma skin cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962113-9

7 January 2021

Consensus guidelines for the management of plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962113-9

7 January 2021

Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962113-9

7 January 2021

European S3-Guidelines on the systemic treatment of psoriasis vulgaris

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962113-9

7 January 2021

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962113-9

7 January 2021

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962113-9

7 January 2021

Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962113-9

7 January 2021

Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962113-9

7 January 2021

Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962113-9

7 January 2021

Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962113-9

7 January 2021

Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962113-9

7 January 2021

Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962113-9

7 January 2021

JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962113-9

7 January 2021

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962113-9

7 January 2021

Dose Response and Pharmacokinetics of Tofacitinib (CP-690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962113-9

7 January 2021

Sensitivity of the Dermatology Life Quality Index to clinical change in patients with psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962113-9

7 January 2021

Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962113-9

7 January 2021

Treating inflammation with the Janus Kinase inhibitor CP-690,550

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962113-9

7 January 2021

Better medication adherence results in greater improvement in severity of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962113-9

7 January 2021

Conversations on psoriasis – what patients want and what physicians can provide: A qualitative look at patient and physician expectations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962113-9

7 January 2021

British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962113-9

7 January 2021

Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962113-9

7 January 2021

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962113-9

7 January 2021

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962113-9

7 January 2021

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962113-9

7 January 2021

Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2814%2962113-9

7 January 2021

10.1016/S0140-6736(14)62113-9

Identifiers

DOI

1 reference

2 August 2017

1 reference